{
    "Trade/Device Name(s)": [
        "MEG-2B Blood Glucose Monitoring System",
        "MEG-2B Pro Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Apex Bio Technology Corp",
    "510(k) Number": "K143750",
    "Predicate Device Reference 510(k) Number(s)": [
        "K120448"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA",
        "NBW"
    ],
    "Summary Letter Date": "May 7, 2015",
    "Summary Letter Received Date": "April 8, 2015",
    "Submission Date": "March 31, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "MEG-2B meter",
        "MEG-2B Pro meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for MEG-2B and MEG-2B Pro Blood Glucose Monitoring Systems for quantitative glucose measurement in capillary whole blood.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from fingertip, forearm, or palm; MEG-2B is for self-testing by lay people at home, MEG-2B Pro is for professional use in healthcare settings; not for diagnosis or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}